242 related articles for article (PubMed ID: 7579404)
21. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
[TBL] [Abstract][Full Text] [Related]
22. Certain HLA antigens are associated with specific morphologic and cytogenetic subsets of acute myeloid leukemia.
Joventino LP; Stock W; Lane NJ; Daly KM; Mick R; Le Beau MM; Larson RA
Leukemia; 1995 Mar; 9(3):433-9. PubMed ID: 7885042
[TBL] [Abstract][Full Text] [Related]
23. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
24. [Immunophenotypic and cytogenetic features of acute myelomonocytic leukemia].
Zhou HF; Li JY; Wu YJ; Yang H; Qiu HR; Li L
Ai Zheng; 2006 Oct; 25(10):1252-5. PubMed ID: 17059770
[TBL] [Abstract][Full Text] [Related]
25. Clinical review on features and cytogenetic patterns in adult acute myeloid leukemia with lymphoid markers.
Cuneo A; Ferrant A; Michaux JL; Boogaerts M; Demuynck H; Bosly A; Doyen C; Carli MG; Piva N; Castoldi G
Leuk Lymphoma; 1993 Mar; 9(4-5):285-91. PubMed ID: 8348065
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibodies in myeloid diseases: prognostic use in acute myeloid leukaemia.
Kristensen JS; Hokland P
Leuk Res; 1991; 15(8):693-700. PubMed ID: 1895750
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
de Nully Brown P; Jurlander J; Pedersen-Bjergaard J; Victor MA; Geisler CH
Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
[TBL] [Abstract][Full Text] [Related]
28. [Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
Reinhardt D; Langebrake C; Creutzig U; Vormoor J; Brune C; Thorwesten M; Ingiliz P; Hrusak O; Dworzak M; Griesinger F
Klin Padiatr; 2002; 214(4):179-87. PubMed ID: 12165899
[TBL] [Abstract][Full Text] [Related]
29. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases.
Dunphy CH; Tang W
Arch Pathol Lab Med; 2007 May; 131(5):748-54. PubMed ID: 17488160
[TBL] [Abstract][Full Text] [Related]
30. Correlation of cytogenetic results with immunophenotype, genotype, clinical features, and ras mutation in acute myeloid leukemia. A study of 235 Chinese patients in Taiwan.
Tien HF; Wang CH; Lin MT; Lee FY; Liu MC; Chuang SM; Chen YC; Shen MC; Lin KH; Lin DT
Cancer Genet Cytogenet; 1995 Oct; 84(1):60-8. PubMed ID: 7497445
[TBL] [Abstract][Full Text] [Related]
31. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
Klobusicka M; Kusenda J; Babusikova O
Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
[TBL] [Abstract][Full Text] [Related]
32. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
33. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients.
Casasnovas RO; Campos L; Mugneret F; Charrin C; Béné MC; Garand R; Favre M; Sartiaux C; Chaumarel I; Bernier M; Faure G; Solary E
Leukemia; 1998 Jan; 12(1):34-43. PubMed ID: 9436918
[TBL] [Abstract][Full Text] [Related]
34. Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias.
Lewis RE; Cruse JM; Webb RN; Sanders CM; Beason K
Exp Mol Pathol; 2007 Oct; 83(2):269-73. PubMed ID: 17603036
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. The Austrian Pediatric Oncology Group.
Fink FM; Köller U; Mayer H; Haas OA; Grümayer-Panzer ER; Urban C; Dengg K; Mutz I; Tüchler H; Gatterer-Menz I
Med Pediatr Oncol; 1993; 21(5):340-6. PubMed ID: 8492748
[TBL] [Abstract][Full Text] [Related]
36. HLA-DR antigen-negative acute myeloid leukemia.
Wetzler M; McElwain BK; Stewart CC; Blumenson L; Mortazavi A; Ford LA; Slack JL; Barcos M; Ferrone S; Baer MR
Leukemia; 2003 Apr; 17(4):707-15. PubMed ID: 12682628
[TBL] [Abstract][Full Text] [Related]
37. Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0).
Stasi R; Del Poeta G; Venditti A; Masi M; Stipa E; Dentamaro T; Cox C; Dallapiccola B; Papa G
Blood; 1994 Mar; 83(6):1619-25. PubMed ID: 8123853
[TBL] [Abstract][Full Text] [Related]
38. [Improved treatment results in children with AML: Results of study AML-BFM 93].
Creutzig U; Berthold F; Boos J; Fleischhack G; Gadner H; Gnekow A; Graubner U; Henze G; Hermann J; Imbach P; Jürgens H; Kabisch H; Körholz D; Niemeyer CM; Reinhardt D; Reiter A; Ritter J; Spaar HJ; Zimmermann M;
Klin Padiatr; 2001; 213(4):175-85. PubMed ID: 11528551
[TBL] [Abstract][Full Text] [Related]
39. [Immunophenotype characteristics and prognosis of acute leukemia patients with cross expressing lymphoid and myeloid lineage associated antigens].
Jiang NG; Chen XM; Zhu HL; Zhong L; Zeng TT; Jia YQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1405-9. PubMed ID: 21176339
[TBL] [Abstract][Full Text] [Related]
40. CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype.
Cascavilla N; Musto P; D'Arena G; Melillo L; Carella AM; Petrilli MP; Sanpaolo G; Carotenuto M
Haematologica; 1998 May; 83(5):392-7. PubMed ID: 9658721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
